Psychiatry International
September 10, 2026
Tommaso Barlattani, Giorgio Sernia, Chiara D’Amelio et al.
Background: Evidence for repeated intranasal esketamine in obsessive–compulsive disorder (OCD) remains preliminary, particularly when OCD co-occurs with treatment-resistant depression (TRD). Methods: We report a 58-year-old woman treated with intranasal esketamine in routine clinical care for TRD; change in obsessive–compulsive symptoms was followed as a secondary observational outcome. Her...
The International Journal of Neuropsychopharmacology
September 9, 2026
Y-H Chan, H-M Chang
Abstract Background Esketamine, the S-enantiomer of ketamine, is an NMDA receptor antagonist approved for treatment-resistant depression (TRD). Although regulated clinical trials suggest a low risk of misuse, concerns remain that esketamine exposure may facilitate transition to ketamine dependence, particularly in East Asia where illicit ketamine is widely available. Aims & Objectives To...
Journal of Psychiatric Research
September 7, 2026
Objective: Treatment-resistant depression (TRD) is associated with severe functional impairment, poor quality of life, and increased suicide risk. This study evaluated the effectiveness of intranasal esketamine on depressive symptoms, hopelessness, suicidal ideation, and quality of life in patients with TRD, exploring whether outcomes differed according to concomitant antidepressant class (SSRI...
Research Square
September 7, 2026
Jennifer L Phillips, Ifeoluwa F. Olaoluwa, Areebah Ahmed et al.
preprint
Abstract Metabolic, inflammatory, and neurotrophic measures may provide complementary insight into biological heterogeneity underlying treatment-resistant depression and response to ketamine-based treatments. However, biomarker studies of ketamine treatment have focused on individual markers or biological domains, most commonly inflammatory or neurotrophic, while metabolic measures remain...
Drug safety
September 2, 2026
You Wang, Alexandra S Storaci, G Caleb Alexander et al.
Treatment-resistant depression (TRD) is associated with elevated suicide risk, but real-world evidence on whether esketamine reduces suicide attempts and intentional self-harm remains limited. The aim was to estimate whether current esketamine exposure was associated with a higher or lower risk of recorded nonfatal, medically attended suicide attempt or intentional self-harm among adults with...
The International Journal of Neuropsychopharmacology
September 1, 2026
S Makhoul, N Abdulameer
Abstract Background Esketamine intranasal spray is FDA-approved for treatment-resistant depression (TRD), but it is not licensed for use in bipolar disorder due to the risk of antidepressants inducing manic or hypomanic episodes. To date, there is limited data on the use of intranasal esketamine in bipolar disorder, and no previous reports of using esketamine as an add-on treatment in patients...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Antidepressant effects of ketamine and esketamine are short lived, often lasting only weeks after multiple treatments. With that in mind, it has been considered addition of psychotherapy may enhance outcomes. One approach, knows as Ketamine Assisted Psychotherapy (KAP) focuses on "integration " of the dissociative experience induced by ketamine, and suggests this may produce...
Medical Science
August 30, 2026
Julia Rogała, Kinga Polityńska, Dominika Ruszel et al.
Treatment-resistant depression occurs in roughly one-third of individuals diagnosed with depression.Ketamine and esketamine have appeared as innovative antidepressant treatments that target the glutamatergic system and deliver promising therapeutic options for patients unresponsive to conventional monoaminergic antidepressants.This review delivers a complete analysis of the mechanisms of...
European Archives of Psychiatry and Clinical Neuroscience
August 29, 2026
Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.
Alpha psychiatry
August 27, 2026
Zhen-Juan Qin, Xiao-Ming Li, Jia-Bao Li et al.
Background: The therapeutic efficacy and safety of intravenous ketamine or esketamine in adolescents with major depressive disorder (MDD) remain insufficiently defined. This systematic review of randomized controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of intravenous ketamine or esketamine in this population. Methods: A comprehensive search of four...